Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr:125 Suppl 2:S55-7.
doi: 10.1016/S0049-3848(10)70014-1.

Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact

F Elice  1 , F Rodeghiero
Affiliations

Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact

F Elice et al. Thromb Res. 2010 Apr.

Abstract

Tumor vasculature and tumor-associated neo-angiogenesis have recently become major targets of antineoplastic therapy. Beside the agents which have already obtained US Food and Drug Administration (FDA) approval for clinical use (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib), many others are being tested in clinical trials. Angiogenesis inhibitors, in particular inhibitors of the vascular endothelial growth factor (VEGF) pathway, have shown significant vascular complications, including both thromboembolic and bleeding events. The definition of the clinical impact of bleeding complications (increase in the rate of hemorrhages in comparison with the control group) and the knowledge of the pathogenesis of this toxicity are very important in order to evaluate the results of many studies using antiangiogenic agents in the treatment of cancer patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources